TOKYO, Nov 15, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Japan Ltd announced today that a TV commercial will be ...

few more so than Eisai, which is developing a package of products and services in Japan for people living with dementia. Its latest venture is an alliance with Tokyo-based Lifenet Insurance Co ...

Eisai's digital tool to allow self-assessment of cognitive performance – NouKNOW – will be used in a Japanese project aimed ... be deployed in Bunkyo City, Tokyo in a dementia monitoring ...

TOKYO (Kyodo) -- A single course of newly approved ... the treatment in Japan of early symptomatic Alzheimer's disease.

A 65-year-old American tourist has been arrested in Japan for carving letters into a wooden gate at a shrine in Tokyo.

Tokyo, Nov. 13 (Jiji Press)--Japan's Central Social Insurance Medical Council, which advises the health minister, approved ...

Japanese drugmaker Eisai is developing a dementia treatment that it aims to commercialise in the US by fiscal 2030, the Nikkei reported on Sunday. The new drug targets a protein called tau ...

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan. Read More on ESALF: Eisai NewsMORE Related Stocks Indices Commodities ...

Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for <a target=_blank href=https:/ ...

Japanese stocks are higher in morning trade, led by gains in tech and real-estate stocks. Concerns about funding costs ease following the Fed’s rate cut overnight. Recruit Holdings is up 3.7% and ...

Eisai Co., Ltd. and Biogen Japan Ltd announced today that a TV commercial will be broadcast nationwide in Japan from November 15 with the aim of increasing public ...